Population pharmacodynamics of cilostazol in healthy Korean subjects
- PMID: 32055555
- PMCID: PMC6989258
- DOI: 10.12793/tcp.2018.26.2.93
Population pharmacodynamics of cilostazol in healthy Korean subjects
Abstract
Cilostazol is used for the treatment of intermittent claudication, ulceration and pain. This study was conducted to develop a population pharmacodynamic (PD) model for cilostazol's closure time (CT) prolongation effect in healthy Korean subjects based on a pharmacokinetic (PK) model previously developed. PD data were obtained from 29 healthy subjects who participated in a study conducted in 2009 at Severance Hospital. The PK model used was a two-compartment model with first order absorption. CT data were best described by a turnover model with a fractional turnover rate constant (Kout ) inhibited by drug effects (Eff), which were represented by a sigmoid Emax model [Eff = Emax · Cγ / (EC 50 γ+Cγ)] with Emax being maximum drug effect, EC 50 drug plasma concentration at 50% of Emax , C drug plasma concentrations, and γ the Hill coefficient. For the selected PD model, parameter estimates were 0.613 hr -1 for Kout , 0.192 for Emax , 730 ng/ml for EC 50 and 5.137 for γ. Sex and caffeine drinking status significantly influenced the baseline CT, which was 85.36 seconds in male non-caffeine drinkers and increased by 15.5% and 16.4% in females and caffeine drinkers, respectively. The model adequately described the time course of CT. This was the first population PD study for cilostazol's CT prolongation effect in a Korean population.
Keywords: Cilostazol; Closure time; Population pharmacodynamic model; Sigmoid Emax model; Turnover model.
Copyright © 2018 Translational and Clinical Pharmacology.
Conflict of interest statement
Conflict of interest: - Authors: The author has no conflict of interest. - Reviewers: Nothing to declare - Editors: Nothing to declare
Figures



References
-
- Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol. 1996;314:197–202. - PubMed
LinkOut - more resources
Full Text Sources